Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s share price was down 4.5% during mid-day trading on Friday . The stock traded as low as C$0.82 and last traded at C$0.84. 17,872 shares traded hands during trading, a decline of 61% from the average session volume of 45,469 shares. The stock had previously closed at C$0.88.
Medicenna Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65. The company has a market capitalization of C$62.84 million, a price-to-earnings ratio of -2.31 and a beta of 1.21. The stock has a 50 day moving average price of C$0.94 and a two-hundred day moving average price of C$1.07.
Medicenna Therapeutics Company Profile
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Recommended Stories
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
